A federal jury in the US has sided with Bristol-Myers Squibb in a patent infringement trial against Gilead Sciences over the CAR-T cell therapy Yescarta (axicabtagene ciloleucel), Bloomberg reported Friday.
The jury in Los Angeles determined that Gilead owes Bristol-Myers Squibb $585 million in damages plus a 27.6% running royalty on sales of the CD19-directed genetically modified autologous T cell immunotherapy. Bristol-Myers Squibb reportedly calculated the royalty to be $167 million through the trial.
Gilead, which gained Yescarta through its $11.9-billion acquisition of Kite Pharma in 2017, said it will appeal the verdict.
Yescarta was approved by the FDA later that year for certain patients with large B-cell lymphoma.
To read more Top Story articles, click here.